Sunitinib (Sutent) is a combined PDGFR and VEGFR inhibitor that is undergoing clinical trials in combination with Zytiga and Prednisone. VEGFR is inolved in metastatic tumour growth and so an inhibitor of this enzyme will be useful in stopping the spread of the cancer and reducing the growth of existing metastases.
Other VEGFR inhibitors that could be combined with Zytiga are:
Cabozantinib (Exelexis) VEGFR2 & Met Kinase
Sorafenib (Nexavar) VEGFR, PDGFR, Raf Kinase
Regorafenib (Stivarga) VEGFR, PDGFR, B-Raf
Vandetanib (Caprelsa, Astra Zeneca) VEGFR, EGFR, Ret Kinase
Cediranib (Recentin, Astra Zeneca) VEGFR
Pazopanib (Votrient, GSK) VEGFR, PDGFR, c-Kit Kinase
Linifanib (Abbot) VEGFR, PDGFR
Tivozanib (AV-951) VEGFR
Dovitinib (TKI-258) VEGFR, FGFR, c-Kit
Axitinib (Inlyta, Pfizer) VEGFR
No comments:
Post a Comment